SOX9 stands for a bio-marker for prostate cancer detection

Hao Zi

Huaihe Hospital of Henan University

Wen-Lin Tao

Huaihe Hospital of Henan University

Lei Gao

Huaihe Hospital of Henan University

Zhao-Hua Yu

Huaihe Hospital of Henan University

Xiao-Dong Bai

Huaihe Hospital of Henan University

Xiao-Dong Li (✉ sdfnoe@126.com)

Huaihe Hospital of Henan University <https://orcid.org/0000-0002-4787-6988>

Primary research

Keywords: SOX9, Diagnosis, Prostate cancer

Posted Date: July 20th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-44291/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Background

Prostate cancer is one of common cancers around the world, and in our country the incidence and mortality of PCa are both increasing. More and more reports have revealed that *SOX9* is involved in various human cancers. In this study, we aimed to explore the relationship between *SOX9* expression and diagnostic value of PCa patients.

Methods

In this study, quantitative real-time PCR (qRT-PCR) was performed to determine the expression of *SOX9* of the 131 PCa patients and 74 healthy volunteers. And receiver operating characteristic (ROC) curve was used to determine the diagnostic value of *SOX9* for PCa patients.

Results

The results of qRT-PCR showed that the expression of serum *SOX9* in PCa patients was higher than that in healthy controls ($P < 0.05$). And the expression of *SOX9* was significantly associated with PSA ($P = 0.001$), differentiation ($P = 0.000$), and lymph node metastasis ($P = 0.000$). Besides, the area under the ROC curve (AUC) was 0.966 with the sensitivity of 93.2% and specificity of 87.8% respectively. The optimal cutoff value of *SOX9* was 2.34.

Conclusions

Our results found that *SOX9* is a novel oncogene for PCa, and may be a novel and effective biomarker for the diagnosis of patients with PCa.

Background

Prostate cancer (PCa) is one of the most common cancers in male genitourinary system. And in the worldwide, the incidence of PCa is at the second of all the malignant tumors only after lung cancer in incidence of elderly men [1]. PCa is a clinically heterogeneous multifocal disease, and the incidence is continuously rising. The carcinogenesis and mechanisms of PCa is multistep process. Because there are no obvious characteristics at the early stages, most PCa patients have already been at advanced stages or accompanied by metastasis when they are diagnosed. Moreover, although prostate-specific antigen (PSA) has been used for the earlier detection of clinically localized PCa, the PSA testing has low specificity for PCa [2–5]. Thus there are no reliable predictors of PCa behavior and aggressiveness. So finding effective biomarkers to achieve early diagnosis and treatment has become very important for PCa patients.

SOX9 belongs to the SRY-related HMG box (SOX) family of developmental transcription factors [6]. As DNA binding proteins, SOXs widely exist in multiple tissues in the process of embryonic development [7, 8]. In mammals, *SOX9* is been widely studied. *SOX9* has a decisive role for sex determination and the development and maturation of bone, testicular, kidney, heart, brain and pancreas [9–14]. The regulation of *SOX9* can occur in multiple links, including transcription, translation, posttranslational modification, nuclear transport and the interaction of coenzyme. And In addition, it was reported that *SOX9* was associated with several human cancers. For example, gastric cancer, non-small cell lung cancer and pancreatic cancer [15–17] What's more, *SOX9* has also been reported in prostate cancer, that it was required for cancer initiation and contribute to PCa tumor growth and invasion [18]. However, *SOX9* there are few reports about the correlation of *SOX9* expression with the diagnosis of PCa patients.

In the current study, we aimed to detect the serum expression level of *SOX9* in PCa patients with qRT-PCR method and to investigate the association between *SOX9* expression and diagnosis of PCa patients.

Methods

Patients and specimens collection

All of 131 PCa cancer patients confirmed by pathologists were finally recruited in the study from Huaihe Hospital of Henan University. 74 healthy volunteers were collected as the control group, and no one had been diagnosed with any malignancy in the group. Our study was approved by the Ethics Committee of Huaihe Hospital of Henan University, and the written consents were also obtained from all participants. The clinicopathological features of the PCa patients were listed in Table 1, including age, tumor size, PSA, differentiation, TNM stage, and lymph node metastasis. The serum samples were taken from all the 131 PCa patients and 74 healthy volunteers, and the samples were collection before patients accepting any surgery and therapy. Then all the collected serum samples were put into blood collection tube of EDTA and stored at -80°C until use.

Table 1
Association of *SOX9* expression with clinicopathological features of PCa patients

Characteristics	Number (n = 131)	SOX9 Expression		χ^2	P value
		Low(n = 60)	High(n = 71)		
Age (years)				0.525	0.469
≥ 65	61	30	31		
< 65	70	30	40		
Tumor size (cm)				0.073	0.787
≥ 3	66	31	35		
< 3	65	29	36		
PSA (ng/ml)				13.817	0.001*
≤ 10	50	22	28		
10–20	39	10	29		
> 20	42	28	14		
Differentiation				17.185	0.000*
Well	54	14	40		
Moderate	41	21	20		
Poor	36	25	11		
TNM stage				0.486	0.486
I + II	72	31	41		
III + IV	59	29	30		
Lymph node metastasis				15.030	0.000*
Negative	79	47	32		
Positive	52	13	39		

RNA extraction and qRT-PCR

Total RNA was isolated with Trizol (Invitrogen) reagent. Then the first-strand cDNA was synthesized by Primescript™ RT reagent Kit (Takara, Japan). In this study the expression of *SOX9* was determined using the SYBR Green® Realtime PCR Master Mix (QPK-201, Toyobo Co, Ltd, Osaka, Japan). The primer sequences of *SOX9* and *β-actin* were as follows: *SOX9* forward: 5'-AGCGAACGCACATCAAGAC-3' and reverse: 5'-GCTGTAGTGTGGGAGGTTGAA-3', *β-actin* forward: 5'-GGTGGCTTTTAGGATGGCAAG-3', reverse:

5'-ACTGGAACGGTGAAGGTGACAG-3'. *β-actin* was used as an internal control. The relative expression level of *SOX9* was normalized to *β-actin* and calculated using the $2^{-\Delta\Delta C_t}$ method.

Statistical analysis

All statistical analyses were performed with software SPSS 19.0 and GraphPad Prism 5. The *SOX9* expression level was presented as mean $\pm$ SD. Student's t-test was used to analyze the expression differences between two groups. The associations between serum *SOX9* expression and various clinicopathological characteristics were assessed using Chi-square tests. To determine the diagnostic performance of serum *SOX9* expression in distinguishing PCa patients from healthy controls, we performed receiver operating characteristic (ROC) analysis. $P < 0.05$ was considered as statistically significant.

Results

Increased expression of *SOX9* in PCa patients

To examine the *SOX9* expression in 131 PCa patients and 74 healthy controls, qRT-PCR was performed. The results in Fig. 1 showed that *SOX9* expression was significantly higher in PCa tissues than that in healthy volunteers ($P < 0.05$).

The correlation of *SOX9* expression with clinicopathologic features of PCa patients

In this study, Chi-square test was used to detect the association between *SOX9* expression level and the clinicopathological data of PCa patients. The results were shown in Table 1. *SOX9* expression was significantly associated with PSA ($P = 0.001$), differentiation ($P = 0.000$), and lymph node metastasis ($P = 0.000$). However, there was no significant association with the age, tumor size and TNM stage of PCa patients (all $P > 0.05$).

Diagnostic value of *SOX9* expression in PCa patients

ROC curves in our study showed that *SOX9* could be used to distinguish PCa patients from the healthy volunteers with the area under the curve (AUC) value of 0.966 (Fig. 2) and sensitivity of 93.2%, specificity of 87.8% respectively. And the optimal cutoff value for *SOX9* expression level is 2.34.

Discussion

PCa is the most prevalent cancer in men and as one of the malignant tumors of male genitourinary system, the biological behaviour of PCa is the most complex and the incidence is the higher in developed countries [19]. In our country, the PCa incidence of upward trend is obvious in recent years. Based on the data of center for disease control and prevention of Shanghai for recent 20 years, the incidence of PCa sharp increased and the advanced metastasis PCa is currently incurable [20]. For PCa, carcinogenesis

and the mechanisms affecting the progression and prognosis are multistep processes [21]. Although the previous reports have shown that many factors including *lncRNA HCG11*, *miR-129*, as well as *TMPRSS2-ERG* fusion gene have affected the development and prognosis of PCa [22–24], the prediction and diagnosis of PCa patients was still poor. Thus it is important to find a novel biomarker to improve the diagnostic efficiency of PCa.

Human SOX family has several members, and the functions of the gene family are various. For example, *SOX* genes regulate development and differentiation of many cell types. *SOX* genes within the same subgroup can counteract the function of the genes in another subgroup and the same *SOX* gene could regulate different stages of development in one cell type [25, 26]. *SOX9* is a member of *SOX* family, which is a developmental transcription factor playing a key role in the regulation of sex determination, cartilage development, intestinal differentiation [27]. At the 7.5 weeks of pregnancy, the expression of *SOX9* can be found in embryonal tissue [28]. In the existed studies, *SOX9* acts as an important role in many tissues and organs [9]. In recent years, researchers have found that as a transcription factor [29, 30], Abnormal expression of *SOX9* is associated with the occurrence of many diseases, including many human cancers. For example, Guo et al. found that the expression of *SOX9* was higher in HCC tissues than adjacent tissues and the overexpression of *SOX9* in HCC tissues is of great predictive value on tumor progression and poor prognosis [31]. Shao et al. found that the expression of *SOX9* in gastric cancer was also higher than that in adjacent non-cancerous tissues. The expression of *SOX9* was associated with the growth, invasion, and metastasis of gastric cancer, as well as the prognosis [32].

Moreover, *SOX9* was also identified as one of the earliest molecular expressed in the primordial prostate. The conditional deletion of *SOX9* demonstrated a requirement for *SOX9* in ventral prostate differentiation and development. The study of Huang et al. reported that *SOX9* expression played an important role in prostate development and the initiation of PCa [18]. The study of Qin et al. showed that the combination of *HIVEP3* and *SOX9* help to predict the tumor progression and prognosis of PCa patients [33]. However, the diagnostic value of *SOX9* in PCa remains still unclear and is an active focus of our current research.

In our study, we found that the expression level of *SOX9* was higher in PCa patients than that in healthy group. The similar result was in agreement with the previous studies. In addition, we also focused on the relationship between the expression level of *SOX9* and the clinicalpathological features of PCa patients. The results showed that the expression level of *SOX9* was significantly correlated with PSA, differentiation, and lymph node metastasis. And the result of ROC curves analysis indicated that the expression of *SOX9* could be used as a diagnostic biomarker for PCa patients.

Conclusions

In conclusion, our current data may provide a novel biomarker for the diagnosis of PCa, but the further investigation should be implement about the *SOX9* acting on PCa patients.

Abbreviations

quantitative real-time PCR (qRT-PCR)

receiver operating characteristic (ROC)

area under the ROC curve (AUC)

Prostate cancer (PCa)

SRY-related HMG box (SOX)

Declarations

Ethics approval and consent to participate

This study was supported by the Ethics Committee of Huaihe Hospital of Henan University and also has been carried out in accordance with the World Medical Association Declaration of Helsinki.

The subjects had been informed the objective. Certainly, written consents were signed by every subject in this study.

Consent for publication

We obtaining permission from participants to publish their data.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

Not applicable.

Authors' contributions

H.Z., W.T. design of the work; L.G., Z.Y. the acquisition, analysis, X.B., X.L. interpretation of data; H.Z., W.T. the creation of new software used in the work; X.B., X.L. have drafted the work or substantively revised it. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

References

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. *Cancer J Clin*. 2013;63(1):11–30.
2. Gronberg H. Prostate cancer epidemiology. *Lancet*. 2003;361(9360):859–64.
3. Kovac E, ElShafei A, Tay KJ, Mendez M, Polascik TJ, Jones JS. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. *J Endourol*. 2016;30(6):624–31.
4. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. *Science translational medicine*. 2012;4(127):127rv123.
5. Bottcher R, Hoogland AM, Dits N, Verhoef EI, Kweldam C, Waranecki P, Bangma CH, van Leenders GJ, Jenster G. Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer. *Oncotarget*. 2015;6(6):4036–50.
6. Lefebvre V, Dumitriu B, Penzo-Mendez A, Han Y, Pallavi B. Control of cell fate and differentiation by Sry-related high-mobility-group box (Sox) transcription factors. *Int J Biochem Cell Biol*. 2007;39(12):2195–214.
7. Wegner M. Secrets to a healthy Sox life: lessons for melanocytes. *Pigment cell research*. 2005;18(2):74–85.
8. Wegner M. From head to toes: the multiple facets of Sox proteins. *Nucleic acids research*. 1999;27(6):1409–20.
9. Gordon CT, Tan TY, Benko S, Fitzpatrick D, Lyonnet S, Farlie PG. Long-range regulation at the SOX9 locus in development and disease. *J Med Genet*. 2009;46(10):649–56.
10. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. *Developmental biology*. 2007;305(1):120–32.
11. Hong CS, Saint-Jeannet JP. Sox proteins and neural crest development. *Semin Cell Dev Biol*. 2005;16(6):694–703.
12. Jakob S, Lovell-Badge R. Sex determination and the control of Sox9 expression in mammals. *FEBS J*. 2011;278(7):1002–9.
13. Akiyama H, Lefebvre V. Unraveling the transcriptional regulatory machinery in chondrogenesis. *J Bone Miner Metab*. 2011;29(4):390–5.
14. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantés J, Bricarelli FD, Keutel J, Hustert E, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. *Cell*. 1994;79(6):1111–20.
15. Santos JC, Carrasco-Garcia E, Garcia-Puga M, Aldaz P, Montes M, Fernandez-Reyes M, de Oliveira CC, Lawrie CH, Arauzo-Bravo MJ, Ribeiro ML, et al: **SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression**. *Cancer research* 2016.
16. Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J, Yu L. miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. *OncoTargets therapy*. 2015;8:1773–83.

17. Kondratyeva LG, Sveshnikova AA, Grankina EV, Chernov IP, Kopantseva MR, Kopantzev EP, Sverdlov ED. Downregulation of expression of mater genes SOX9, FOXA2, and GATA4 in pancreatic cancer cells stimulated with TGFbeta1 epithelial-mesenchymal transition. *Doklady Biochemistry biophysics*. 2016;469(1):257–9.
18. Huang Z, Hurley PJ, Simons BW, Marchionni L, Berman DM, Ross AE, Schaeffer EM. Sox9 is required for prostate development and prostate cancer initiation. *Oncotarget*. 2012;3(6):651–63.
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *Cancer J Clin*. 2011;61(2):69–90.
20. Zhang W, Xiang YB, Liu ZW, Fang RR, Ruan ZX, Sun L, Gao LF, Jin F, Gao YT. [Trends analysis of common urologic neoplasm incidence of elderly people in Shanghai, 1973–1999]. *Ai zheng = Aizheng = Chinese journal of cancer*. 2004;23(5):555–8.
21. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. *European urology*. 2012;61(3):549–59.
22. Zhang Y, Zhang P, Wan X, Su X, Kong Z, Zhai Q, Xiang X, Li L, Li Y. Downregulation of long non-coding RNA HCG11 predicts a poor prognosis in prostate cancer. *Biomedicine pharmacotherapy = Biomedecine pharmacotherapie*. 2016;83:936–41.
23. Xu S, Yi XM, Zhang ZY, Ge JP, Zhou WQ. **miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma**. *Molecular medicine reports* 2016.
24. Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, et al. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer. *Anticancer research*. 2016;36(9):4787–93.
25. Cui J, Shen X, Zhao H, Nagahama Y. Genome-wide analysis of Sox genes in Medaka (*Oryzias latipes*) and their expression pattern in embryonic development. *Cytogenet Genome Res*. 2011;134(4):283–94.
26. Gracz AD, Magness ST. Sry-box (Sox) transcription factors in gastrointestinal physiology and disease. *American journal of physiology Gastrointestinal liver physiology*. 2011;300(4):G503–15.
27. Endo Y, Deonauth K, Prahalad P, Hoxter B, Zhu Y, Byers SW. Role of Sox-9, ER81 and VE-cadherin in retinoic acid-mediated trans-differentiation of breast cancer cells. *PloS one*. 2008;3(7):e2714.
28. Moniot B, Biau S, Faure S, Nielsen CM, Berta P, Roberts DJ. de Santa Barbara P: **SOX9 specifies the pyloric sphincter epithelium through mesenchymal-epithelial signals**. *Development*. 2004;131(15):3795–804.
29. Levay AK, Peacock JD, Lu Y, Koch M, Hinton RB Jr, Kadler KE, Lincoln J. Scleraxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. *Circulation research*. 2008;103(9):948–56.
30. Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA, Hanley NA. Ectopic SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis. *J Biol Chem*. 2008;283(20):14063–71.

31. Guo X, Xiong L, Sun T, Peng R, Zou L, Zhu H, Zhang J, Li H, Zhao J. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma. Diagnostic pathology. 2012;7:44.

32. Shao CM, Shao QS, Yao HB, Zhao ZK, Xu J, Zhao ZS, Tao HQ. [Association of SOX9 expression and prognosis in patients with gastric cancer]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery. 2012;15(7):736–9.

33. Qin GQ, He HC, Han ZD, Liang YX, Yang SB, Huang YQ, Zhou L, Fu H, Li JX, Jiang FN, et al. Combined overexpression of HIVEP3 and SOX9 predicts unfavorable biochemical recurrence-free survival in patients with prostate cancer. OncoTargets therapy. 2014;7:137–46.

Tables

Table 1. Association of *SOX9* expression with clinicopathological features of PCa patients

Characteristics	Number (n=131)	SOX9 Expression		χ^2	P value
		Low(n=60)	High(n=71)		
Age (years)				0.525	0.469
≥65	61	30	31		
<65	70	30	40		
Tumor size (cm)				0.073	0.787
≥3	66	31	35		
<3	65	29	36		
PSA (ng/ml)				13.817	0.001*
≤10	50	22	28		
10-20	39	10	29		
>20	42	28	14		
Differentiation				17.185	0.000*
Well	54	14	40		
Moderate	41	21	20		
Poor	36	25	11		
TNM stage				0.486	0.486
I+II	72	31	41		
III+IV	59	29	30		
Lymph node metastasis				15.030	0.000*
Negative	79	47	32		
Positive	52	13	39		

Figures

Figure 1

Serum SOX9 expression levels evaluated by qRT-PCR in PCa patients and healthy controls (*, $P < 0.05$).

Figure 2

ROC analysis for evaluation of the accuracy of serum SOX9 to distinguish PCa patients from healthy volunteers.